Gracell Biotechnologies to Host KOL Webinar on Multiple Myeloma on May 22nd
15 Maio 2023 - 10:15AM
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell”), a global
clinical-stage biopharmaceutical company dedicated to developing
highly efficacious and affordable cell therapies for the treatment
of cancer and autoimmune diseases, today announced that it will
host a key opinion leader (KOL) webinar on May 22, 2023 at 9:00 am
ET.
Gracell Biotechnologies’ KOL event will feature participation
from management and key opinion leader Saad Z. Usmani, MD, MBA,
FACP, Myeloma & Cellular Therapy Specialist, Chief of Myeloma
Service at Memorial Sloan Kettering Cancer Center. The discussion
will focus on the treatment landscape for multiple myeloma and
highlight the unmet clinical needs in the U.S. A live question and
answer session will follow the formal presentation.
KOL Webinar and Webcast
Details:Title: Gracell Biotechnologies
Key Opinion Leader Webinar on Multiple MyelomaDate: Monday, May
22nd, 2023 at 9:00am ETRegistration Link for Video Webcast:
event.gracellbio.com
Dial-in information for phone participants: Domestic dial-in:
(800) 715-9871 International dial-in: (646) 307-1963Conference ID:
5760854
A replay of the event will be available
on ir.gracellbio.com shortly after the conclusion of the
event for 90 days.
About GracellGracell Biotechnologies
Inc. ("Gracell") is a global clinical-stage biopharmaceutical
company dedicated to discovering and developing breakthrough cell
therapies. Leveraging its pioneering FasTCAR and TruUCAR technology
platforms and SMART CARTTM technology module, Gracell is
developing a rich clinical-stage pipeline of multiple autologous
and allogeneic product candidates with the potential to overcome
major industry challenges that persist with conventional CAR-T
therapies, including lengthy manufacturing time, suboptimal cell
quality, high therapy cost and lack of effective CAR-T therapies
for solid tumors. For more information on Gracell, please
visit http://www.gracellbio.com/.
Follow @GracellBio on LinkedIn.
Media contacts
Marvin Tang
marvin.tang@gracellbio.com
Jessica Laub
jessica.laub@westwicke.com
Investor contacts
Gracie Tong
gracie.tong@gracellbio.com
Stephanie Carrington
stephanie.carrington@westwicke.com
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Gracell Biotechnologies (NASDAQ:GRCL)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024